LONG TERM REMISSION/SURVIVAL OVER 8 YEARS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) TREATED WITH ICT-107 DENDRITIC CELL-BASED IMMUNOTHERAPY (PHASE I)

被引:0
|
作者
Phuphanich, S. [1 ]
Wheeler, C. [1 ]
Rudnick, J. [1 ]
Hu, J. [1 ]
Mazer, M. [1 ]
Nuno, M. [1 ]
Sanchez, C. [1 ]
Chu, R. [1 ]
Black, K. [1 ]
Yu, J. [1 ,2 ]
机构
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] ImmunoCellular Therapeut Ltd, Woodland Hills, CA USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OS2.5
引用
收藏
页码:5 / 5
页数:1
相关论文
共 21 条
  • [21] PHASE 2 TRIAL OF SL-701+BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED GLIOBLASTOMA (GBM) MEETS PRIMARY ENDPOINT OF OS-12, WITH PRELIMINARY CORRELATION BETWEEN LONG-TERM SURVIVAL AND TARGET-SPECIFIC CD8+T CELL IMMUNE RESPONSE
    Peereboom, David
    Nabors, L. Burt
    Kumthekar, Priya
    Badruddoja, Michael
    Fink, Karen
    Lieberman, Frank
    Phuphanich, Surasak
    Dunbar, Erin
    Walbert, Tobias
    Schiff, David
    Tran, David
    Ashby, Lynn
    Butowski, Nicholas
    Iwamoto, Fabio
    Lindsay, Ross
    Bullington, John
    Schulder, Michael
    Sherman, Jonathan
    Brooks, Chris
    Reardon, David
    NEURO-ONCOLOGY, 2018, 20 : 2 - 2